Bluebird bio Inc

Bluebird bio — Investor Presentation (December 2014)

24 slides from Bluebird bio's investor presentation, Dec 10, 2014

  1. Slide 1: Making Hope A Reality

    Making Hope A Reality December 10, 2014 Nasdaq : BLUE Exhibit 99.1

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue

  3. Slide 3: Overview – bluebird bio

    Overview – bluebird bio Potential for one-time transformative treatments for severe genetic and orphan diseases Encouraging clinical efficacy and safety data in beta thalassemia and CCALD with an emerging pipeline, including a clinical program in sickle cell disease Industrialized gene delivery plat

  4. Slide 4: bluebird Pipeline

    bluebird Pipeline * The Phase II/III Starbeam Study is our first clinical study of our current Lenti-D viral vector and product candidate. ** The Phase I/II HGB-205 and Northstar Studies are our first clinical studies of our current LentiGlobin viral vector and product candidate. CNS Diseases Childh

  5. Slide 5: ASH Data Demonstrates First Four Patients Treated with β-thalassemia Major are Transfusion-Free

    ASH Data Demonstrates First Four Patients Treated with β-thalassemia Major are Transfusion-Free Clinical data to-date from both Northstar and HGB-205 studies continue to be very promising: First four patients with at least three months of follow-up are transfusion-free Early, robust and steadily ris

  6. Slide 6: β-thalassemia Major: Disease Overview

    Β-thalassemia Major: Disease Overview Our focus is β-thalassemia major (e.g. transfusion-dependent) Most severe form Monogenic, severe anemia Loss of or reduced β-globin production Poor quality of life & shortened lifespan Current Treatments Disease Epidemiology Global β-thalassemia prevalence ~288K

  7. Slide 7: Our Manufacturing Platform – How it Works

    Our Manufacturing Platform – How it Works (~40 hrs) Bone marrow harvest

  8. Slide 8: β-thalassemia: Clinical Trial Summary

    Β-thalassemia: Clinical Trial Summary Second Generation BB305 Vector Northstar Study HGB-205 Trial Location(s) US, Australia, Thailand France Phase I/II I/II N 15 7 Indication β-thalassemia major β-thalassemia major & severe sickle cell disease Sites Multi-center 1 Status Enrollment ongoing Enrollme

  9. Slide 9: Study Enrollment Disposition

    Study Enrollment Disposition Consented N=15 Ineligible N=2 Eligible N=13* Stem Cell Harvest Performed N=10 Apheresis Failure N=1 Transduction Complete N=7 Drug Product Infused N=5 Transduction in Progress N=2 Consented N=5 Ineligible N=1 Eligible N=4 Stem Cell Harvest Performed N=3 Transduction Comp

  10. Slide 10: Demographics and Baseline Characteristics for Treated Subjects with β-thalassemia

    Demographics and Baseline Characteristics for Treated Subjects with β-thalassemia Data as Presented at ASH 2014 TRIAL Northstar* HGB-205 Subject 1102 1104 1106 1107 1108 1201 1202 Age/Sex 18/F 21/F 20/F 26/F 18/F 18/F 16/M Country of birth USA Thailand Pakistan Australia USA Syria France Genotype β0

  11. Slide 11: ` Subject 1102 Subject 1104 Subject 1106 Subject 1107 Subject 1201 Subject 1202 Neutrophil

    ` Subject 1102 Subject 1104 Subject 1106 Subject 1107 Subject 1201 Subject 1202 Neutrophil engraftment ANC > 500/µL Day +17 Day +18 Day +29 Day +14 Day +13 Day +15 Platelet engraftment Unsupported platelet count > 20,000/µL Day +28 Day +31 Day +30 Day +27 Day +17 Day +24 Non-laboratory ≥Grade 3 AEs

  12. Slide 12: Vector Copy Number and βA-T87Q-globin Expression Over Time

    Vector Copy Number (VCN) and βA-T87Q- globin Expression for Subjects with β-thalassemia Over Time Mean VCN (copies/cell) Vector Copy Number in Drug Product and Peripheral Blood HbAT87Q (g/dL) βA-T87Q-globin Expression in Peripheral Blood Months post-infusion Months post-infusion

  13. Slide 13: Consistently Robust βA-T87Q-globin Levels

    3.8 6.8 7.7 9.6 Color by Hb Type HbAT87Q Hb A2 Hb F Hb E Hb A Color by Hb Type Consistently Robust βA-T87Q-globin Levels Hb g/dL Months post-drug product infusion

  14. Slide 14: All Subjects with at Least Months of Follow-up are Transfusion-Free

    All Subjects with at Least 3 Months of Follow-up are Transfusion-Free, Regardless of Genotype Days Transfusion-Free Subject Months post-infusion Days Transfusion-Free as of December 1, 2014 β0/βE 94 days 359 days 260 days 154 days β0/βE β0/βE β0/β0

  15. Slide 15: Sickle Cell Disease: Disease Overview

    Sickle Cell Disease: Disease Overview Monogenic, severe anemia Polymerization of β-globin chains deforms / sickles red blood cells Poor quality of life Pain crises, stroke, splenomegaly Shortened lifespan Non curative treatments Hydroxyurea Blood transfusions Pain management Allogeneic Transplant Ma

  16. Slide 16: Evidence for Why BB305 globin May Work for Sickle Cell Disease

    Evidence for Why BB305 globin May Work for Sickle Cell Disease (SCD) BB305 globin incorporates an anti-sickling amino acid that is found in fetal hemoglobin (glutamine at position 87) Anti-sickling activity of βA-T87Q-globin has been demonstrated in a mouse model of SCD (Science 2001) Elevated fetal

  17. Slide 17: High T87Q-globin Proportion Observed in Thalassemia Subjects is Promising for SCD

    Proportion of total hemoglobin carrying βA-T87Q chains Months post drug product infusion High T87Q-globin Proportion Observed in Thalassemia Subjects is Promising for Potential SCD Outcomes βA-T87Q-globin Proportion in Peripheral Blood

  18. Slide 18: Data Summary of First Subject with SCD Treated in HGB-205

    Data Summary of First Subject with SCD Treated in HGB-205 First ever treatment of a subject with SCD using gene therapy Drug Product infusion in October 2014 Tolerated transplantation well, without serious adverse events Neutrophil engraftment on Day 37; platelet engraftment pending Currently too ea

  19. Slide 19: HGB-206: SCD Study is Now Active

    HGB-206: SCD Study is Now Active HGB-206 Trial Location US Phase I N 8 Indication Severe sickle cell disease Clinical Endpoints* Primary : safety Secondary: clinical events Sites Multi-Center Status Enrollment open *Measure red cell function tests, hemolysis markers; frequency of clinical events sec

  20. Slide 20: Data will Continue to Drive β-thalassemia and SCD Programs

    Data will Continue to Drive β-thalassemia and SCD Programs Promising clinical data to-date from both Northstar and HGB-205 studies: Early, robust and steadily rising βA-T87Q-globin levels First four patients transfusion-free for at least 3 months, one of whom is out 12 months First subject with SCD

  21. Slide 21: Looking Forward: Our Strategic Intent

    Lead the gene therapy revolution Deliver clinically transformative data across both platforms Invest in global infrastructure Leverage capabilities and technologies to enable deeper and broader pipeline Lentiviral Gene Delivery – High Quality and Large Scale Cellular Transduction Capabilities – Glob

  22. Slide 22: 2014 – Substantial Progress

    2014 – Substantial Progress 2014 First subject transplanted in Northstar Study Preliminary HGB-205 data in β-Thalassemia presented at EHA First subject with sickle cell disease infused in HGB-205 Launched HGB-206 sickle cell study Preliminary Northstar & HGB-205 data in β-thalassemia presented at AS

  23. Slide 23: bluebird bio 2020: The Gene Therapy Product Company

    bluebird bio 2020: The Gene Therapy Product Company 2010 - 2014 2015 - 2020 Broad Gene Therapy Infrastructure Translational Development Manufacturing Clinical Regulatory Product Pipeline Internal Programs Partnerships

  24. Slide 24: Why We Do What We Do

    Why We Do What We Do Our Vision – Make Hope a Reality Seeking to transform the lives of patients with severe genetic and orphan diseases through the development of innovative gene therapy products. Ethan Cameron Aidan

bluebird bio — Investor Presentation (December 2014) on 6ix